Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Cellectis SA ( (CLLS) ) is now available.
On May 11, 2026, Cellectis reported first-quarter 2026 results and highlighted progress across its pipeline, including pivotal Phase 2 development of lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia and Phase 1 development of eti-cel for relapsed or refractory non-Hodgkin lymphoma. The company plans an interim Phase 2 analysis for lasme-cel and a full Phase 1 dataset for eti-cel in the fourth quarter of 2026, while maintaining a favorable safety profile and high response rates in early data.
Cellectis also showcased its TALEM TALE-based epigenetic editing platform, which enables durable gene silencing without cutting DNA and was featured at the ASGCT meeting in May 2026, underscoring its push into potentially safer genome-editing approaches. The company’s partnered programs advanced as well, with Allogene reporting promising interim ALPHA3 data for cema-cel in large B-cell lymphoma and Iovance enrolling patients in a Phase 1/2 trial of an edited TIL therapy, while Cellectis ended the quarter with $188 million in cash providing runway into the fourth quarter of 2027.
In parallel, Cellectis reported that Thermo Fisher’s subsidiary Life Technologies Corporation moved to terminate certain 2014 license agreements and initiated arbitration over alleged underpaid royalties, which Cellectis disputes as invalid and without merit. The combination of advancing internal and partnered programs, a finite cash runway, and a newly contested licensing dispute frames a critical period for Cellectis’ operational execution and its positioning within the competitive allogeneic cell therapy landscape.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is held back primarily by weak financial performance—persistent losses, renewed 2025 cash burn, and rising leverage—partly offset by a relatively constructive technical setup with the stock trading above several key moving averages. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company that uses a proprietary gene-editing platform to develop allogeneic, off-the-shelf cell and gene therapies. The company focuses on oncology and other areas of high unmet medical need, leveraging partnerships with AstraZeneca, Servier and Allogene, and collaborators such as Iovance to advance CAR-T and TIL-based treatments.
Average Trading Volume: 39,950
Technical Sentiment Signal: Buy
Current Market Cap: $272.1M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.